ics Inc Brief article
Selected Abstract
Ocera drug candidate shows promise, could gain orphan status.(BIOTECH)(Ocera Therapeutics Inc.)(Brief article)
Ocera Therapeutics Inc. reported positive Phase 2 results for a drug candidate to treat pouchitis, a common problem following j-pouch surgery for ulcerative colitis, during the recent American College of Gastroenterology annual meeting. The privately held biopharmaceutical company, focused on ... October 22, 2007; San Diego Business Journal
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
